Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer

Phase 1 Terminated 31 enrolled Mersana Therapeutics IQVIA Biotech · collab PSI CRO · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Phase 1 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks in combination with Carboplatin in participants with high-grade serous ovarian cancer (HGSOC, including fallopian tube and primary peritoneal cancer). The trial consists of dose escalation (DES) and expansion (EXP) portion. In addition to safety assessments, the pharmacokinetics of the drug will be assessed along with ADC activity.

Timeline

Start: 2021-06-11
Primary completion: 2023-10-03
Completion: 2023-10-03

Outcome

Outcome not reported

Stopped: “Study Terminated by Sponsor”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	upifitamab rilsodotin	Other / unclassified	—	Intravenous
Background	Carboplatin	Small molecule	—	—

Indications

No indication recorded.